Please select each case study you wish to download.
Case: This project calculated the expected effect on health and economic outcomes of a proposed new program for managing people with diabetes in Kaiser Permanente, called "A-L-L". The Model predicted that the A-L-L program would simultaneously improve the health of Kaiser Permanente's members while also saving an estimated $38 million annually in unnecessary healthcare costs. Given the outcomes from the Archimedes Model were so promising, Kaiser Permanente decided to launch and heavily promote a program-wide effort to provide the A-L-L program to all patients with diabetes. Conclusion: An independent follow-up study 5 years later confirmed that reduction of healthcare cost and number of lives saved predicted by the Archimedes Model were accurate.
Case: The American Diabetes Association used the Archimedes Model to extend the three-year Diabetes Prevention Program (DPP) trial and compare the long-term effects of current care, metformin, and lifestyle modification on the incidence of diabetes and costs in high-risk individuals. Conclusion: The Model showed that, after 30 years, the lifestyle modification program would reduce the relative risk of a high-risk person developing diabetes by 15%. Compared with not implementing any prevention program, the expected 30-year cost per quality-adjusted life-year of the lifestyle intervention was calculated to be around $143,000. As a result, the ADA has encouraged the development and implementation of interventions that are far less costly than the interventions used in the DPP.
Case: This project calculated the expected event rate in a control population of patients at risk for a Major Adverse Cardiac Event (MACE). Conclusion: This information enabled a major pharmaceutical company to tune the enrollment optimally in a clinical trial evaluating a candidate compound targeting a novel cardiovascular biomarker.
Case: The Preventive Health Partnership, a collaboration between the ACS, AHA, and ADA, wanted to identify which individual single or combined health care prevention activities, when implemented throughout adulthood, will lead to improvements in health, quality of life, and medical costs for patients who enter Medicare during the years spanning 2009-2033. Conclusion: Notable conclusions include that, at 100% clinical performance, heart disease related deaths would decrease by 59%, and, at realistic clinical performance, mortality reductions for MI reduced by 33%; stroke by 19%.
Case: A major pharmaceutical company wanted to identify which candidate drug, among six in the customer's clinical development pipeline, would offer the greatest long-term health outcomes and costs benefits. Conclusion:The study shows how predicting the long-term health and cost outcomes for each candidate in a pipeline of preclinical compounds is a high-value, low-cost, much faster means of choosing the right ones to advance to clinical trials.
